-60%

est. 2Y upside i

Climate Tech

Automated factory to produce insect protein for farm animals.

Rank

#1409

Sector

Agri-tech / Sustainable Protein

Est. Liquidity

~4Y

Data Quality

Data: Medium

Entocycle operates in a high-growth agri-tech sector with a strong competitive moat built on proprietary automation and computer vision.

Last updated: March 10, 2026

Bull (22%)+300%

Entocycle's proprietary computer vision and automation technology achieves widespread adoption across the rapidly expanding insect farming industry, securing major licensing deals with global agri-food players. Successful navigation of regulatory frameworks and strategic partnerships with companies like Siemens accelerate market penetration, driving revenue to over $100M by 2028 and justifying an $800M valuation (4x current).

Base (48%)+50%

Entocycle continues to grow steadily, expanding its technology licensing and insect sales within the pet and animal feed markets. While facing competition from other insect farming tech providers, its strong moat allows it to capture a meaningful share of the growing $1.0B SAM. This leads to approximately $30M in revenue by 2028 and a $300M valuation (1.5x current).

Bear (30%)-70%

Slower-than-expected regulatory approvals for insect protein in key markets, coupled with aggressive entry by large agri-tech incumbents developing or acquiring similar automation systems, significantly constrains Entocycle's market share. This results in slower revenue growth, increased capital burn, and a down round, leading to a $60M valuation (0.3x current) where common stock holders see minimal returns due to the substantial liquidation preferences.

Est. time to liquidity~4.0 years

Preference Stack Risk

high

Investors hold $50M in liquidation preferences. In an exit at or below $200M, common stock holders would be significantly impacted, potentially receiving little to nothing if the exit is near the total funding amount.

Dilution Risk

high

As a Series A company with substantial funding, further equity rounds (Series B, C, etc.) are highly probable, leading to additional dilution for existing common shareholders.

Secondary Liquidity

none

There is no indication of active secondary markets or tender offers for Entocycle's shares at this stage, which is typical for a company at this stage.

Other — 2 roles

View all 2 open roles at Entocycle →

Last updated: March 10, 2026

Questions to Ask at the Interview

Strategic questions based on Entocycle's data — designed to show you've done your homework.

  • 1

    “Given the 'medium' incumbent threat from large agri-tech players, how is Entocycle strategically positioning its technology solutions to avoid direct competition with their potential in-house development or acquisitions, particularly in the next 2-3 years?”

  • 2

    “With an estimated $6.7M in annual revenue and a focus on both insect sales and technology licensing, what are the key metrics and milestones the company is prioritizing to demonstrate capital efficiency and accelerate towards profitability, especially considering the high capital intensity of the sector?”

  • 3

    “Considering the $50M in total funding and the current stage, what is the company's anticipated timeline and strategy for a liquidity event, and how does the preference stack impact the expected returns for common stock holders?”

Community

Valuation Sentiment

Our model estimates -60% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.